Sandbox/intraabdominal: Difference between revisions
No edit summary |
|||
Line 447: | Line 447: | ||
! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center| {{fontcolor|#FFF|Recommended Regimen}} | ! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center| {{fontcolor|#FFF|Recommended Regimen}} | ||
|- | |- | ||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Cefazolin]] 1 g IV q8h''''' | | style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Cefazolin]] 1-2 g IV q8h''''' | ||
|- | |- | ||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | OR | | style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | OR | ||
|- | |- | ||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Cefuroxime]] | | style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Cefuroxime]] 1.5 g IV q8h''''' | ||
|- | |- | ||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | OR | | style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | OR | ||
|- | |- | ||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Ceftriaxone]] | | style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Ceftriaxone]] 1-2 g IV q12-24h''''' | ||
|- | |- | ||
|} | |} | ||
Line 480: | Line 480: | ||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | OR | | style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | OR | ||
|- | |- | ||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Ciprofloxacin]] | | style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Ciprofloxacin]] 400 g IV q12h''''' | ||
|- | |- | ||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | OR | | style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | OR | ||
|- | |- | ||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Levofloxacin]] | | style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Levofloxacin]] 750 mg IV q24h''''' | ||
|- | |- | ||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | OR | | style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | OR | ||
|- | |- | ||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Cefepime]] | | style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Cefepime]] 2 g IV q8-12h''''' | ||
|- | |- | ||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | PLUS | | style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | PLUS | ||
|- | |- | ||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Metronidazole]] 500 g | | style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Metronidazole]] 500 mg IV q8-12h or 1.5 g q24h''''' | ||
|- | |- | ||
|} | |} | ||
Line 517: | Line 517: | ||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | OR | | style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | OR | ||
|- | |- | ||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Ciprofloxacin]] | | style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Ciprofloxacin]] 400 g IV q12h''''' | ||
|- | |- | ||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | OR | | style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | OR | ||
|- | |- | ||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Levofloxacin]] | | style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Levofloxacin]] 750 mg IV q24h''''' | ||
|- | |- | ||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | OR | | style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | OR | ||
|- | |- | ||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Cefepime]] | | style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Cefepime]] 2 g IV q8-12h''''' | ||
|- | |- | ||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | PLUS | | style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | PLUS | ||
|- | |- | ||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Metronidazole]] 500 g | | style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Metronidazole]] 500 mg IV q8-12h or 1.5 g q24h''''' | ||
|- | |- | ||
|} | |} | ||
Line 554: | Line 554: | ||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | OR | | style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | OR | ||
|- | |- | ||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Ciprofloxacin]] | | style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Ciprofloxacin]] 400 g IV q12h''''' | ||
|- | |- | ||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | OR | | style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | OR | ||
|- | |- | ||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Levofloxacin]] | | style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Levofloxacin]] 750 mg IV q24h''''' | ||
|- | |- | ||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | OR | | style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | OR | ||
|- | |- | ||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Cefepime]] | | style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Cefepime]] 2 g IV q8-12h''''' | ||
|- | |- | ||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | PLUS | | style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | PLUS | ||
|- | |- | ||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Metronidazole]] 500 g | | style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Metronidazole]] 500 mg IV q8-12h or 1.5 g q24h''''' | ||
|- | |- | ||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | PLUS | | style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | PLUS |
Revision as of 17:58, 12 June 2014
Initial Empiric Treatment of Extra-biliary Community-acquired Complicated Intra-abdominal Infection
▸ Click on the following categories to expand treatment regimens.
Pediatric patients ▸ Single agent ▸ Combination Adults, mild-to-moderate severity ▸ Single agent ▸ Combination Adults, high risk or severity ▸ Single agent ▸ Combination |
|
Empiric Antimicrobial Therapy for Health Care-Associated Complicated Intra-abdominal Infection
▸ Click on the following categories to expand treatment regimens.
Multidrug resistant gram-negative bacilli ▸ Recommended Regimen ESBL-Enterobacteriaceae ▸ Recommended Regimen Pseudomonas aeruginosa >20% resistant to ceftazidime ▸ Recommended Regimen MRSA ▸ Recommended Regimen |
|
Initial Empiric Treatment of Biliary Infection in Adults
▸ Click on the following categories to expand treatment regimens.
Community-acquired acute cholecystitis of mild-to-moderate severity ▸ Recommended Regimen Community-acquired acute cholecystitis of severe physiologic disturbance, advanced age, or immunocompromised state ▸ Recommended Regimen Acute cholangitis following bilio-enteric anastamosis of any severity ▸ Recommended Regimen Health care–associated biliary infection of any severity ▸ Recommended Regimen |
|